Whether you need assistance with one part of your clinical trial or a full service UK CRO, PHARMExcel supports sponsors to design and deliver robust, patient centred urology clinical trials. We work with biotechs, medtech companies, charities and NHS or academic sponsors, providing agile, hands on support from early feasibility through to close out and reporting.
Urology clinical trials explained
Urology clinical trials are essential for improving care across a wide range of conditions affecting the urinary tract, pelvic floor and male reproductive system. These studies may involve sensitive symptoms, intimate assessments, patient-reported outcomes and long term follow up, all of which need careful handling in both protocol design and site delivery. Trial plans therefore need to balance scientific rigour with privacy, dignity and practical feasibility for patients and investigators.
Urology also spans a broad and varied clinical landscape, which means study design, site selection and patient pathways need to be tailored to the specific indication and population.
| Urology area | Example conditions and study focus |
| Prostate | Benign prostatic hyperplasia (BPH), prostate cancer, chronic prostatitis |
| Bladder and urinary | Bladder cancer, urinary incontinence, urinary tract infection, voiding disorders |
| Pelvic floor | Pelvic floor disorders, male incontinence, functional voiding dysfunction |
| Male reproductive health | Erectile dysfunction, Peyronie’s disease, premature ejaculation, male fertility evaluation |
| Upper urinary tract | Nephrolithiasis, pyelonephritis, renal insufficiency |
Why urology trials need specialist expertise
Urology studies can be complex because they often combine objective clinical measures with highly personal symptom reporting. Endpoints may include urinary function assessments, voiding diaries, symptom scores, imaging findings, anatomical evaluation and quality of life measures. In some studies, these need to be interpreted alongside procedural outcomes or longer term functional changes, which adds further complexity to data collection and site training.
The patient experience also needs careful thought. Urology trials may involve intimate symptoms, potentially embarrassing procedures or conditions that affect quality of life in a very personal way. This means privacy, clear communication and acceptable visit schedules are not just ethical considerations, but practical drivers of study feasibility and retention. In pelvic floor, continence and male reproductive studies in particular, the way a protocol is delivered can have a significant impact on participant willingness to engage.
Operationally, many urology studies depend on access to sites with the right procedural capability, specialist investigators and established patient pathways. Studies involving imaging, biopsies, functional testing or device-assisted assessments require centres that can deliver those processes consistently and in line with protocol requirements. Working with a CRO that understands these clinical and operational nuances helps to reduce avoidable amendments, improve study feasibility and protect data quality.
Our approach as your urology CRO partner
Sponsors choose PHARMExcel when they need a partner that can operate as an extension of their own team rather than a distant service provider. As a smaller organisation, we offer direct access to experienced senior staff and continuity of the same core project team throughout the life of your urology trial. This allows for faster responses, informed discussions around risk and mitigation, and a collaborative approach when challenges arise.
Our work is underpinned by a formal quality management system and adherence to GCP, but we apply these standards in a way that remains flexible and proportionate to the needs of each study. We take time at the outset to understand your programme, internal ways of working and expectations for communication and reporting. For overseas sponsors, our knowledge of NHS and academic research environments helps to bridge the gap between global plans and UK site realities.
Commercially, our aim is to give you clarity and control. We provide transparent, itemised budgets and can shape our involvement around your internal capabilities, from full service urology CRO support to focused assistance with defined aspects of your programme.
Governance and oversight across specialist urology networks
Urology studies often depend on access to the right specialist centres, experienced investigators and site teams that understand the demands of urinary, pelvic floor and male reproductive research. PHARMExcel brings governance and oversight to this process by helping sponsors identify the most appropriate urology clinics, surgical units, continence services and centres of excellence for their protocol, based on patient population, site capability and study complexity.
Where studies involve specialist procedures, imaging, symptom monitoring tools or patient-reported outcome collection, we work with sponsors and sites to ensure those requirements are embedded through the right network of centres and partners. Our role is not to perform these procedures directly, but to provide the governance, oversight and coordination needed to ensure they are delivered consistently and in line with protocol requirements.
For studies involving sensitive pathways or harder to reach patient populations, this network-led approach is particularly valuable. It allows sponsors to plan realistic site strategies and referral routes while maintaining close oversight of timelines, participant burden and operational risk.
Urology endpoints, patient-reported outcomes and study feasibility
For each new study, we work with sponsors and investigators to test core assumptions, sense check eligibility criteria and ensure visit schedules and assessments can be delivered reliably at the proposed sites. Because we understand the pressures on specialist urology services, we focus on pragmatic solutions that support site engagement, feasible recruitment pathways and high quality data rather than idealised but impractical designs.
This is especially important in urology trials where voiding diaries, symptom scores, ePRO collection, urinary function assessments or long term follow up can create a significant burden for patients and study teams. A well planned protocol does more than satisfy scientific objectives – it also needs to fit real clinic pathways, site capacity and the lived experience of the patient population.
As a specialist UK CRO, we are particularly well placed to support sponsors who are new to the UK research environment. We provide clear, candid feedback on feasibility, realistic timelines and the types of centres most suited to your protocol, helping you to plan a trial that works on paper and in practice.
Discuss your next urology study with us
Whether you are planning an early phase urology trial in the UK or expanding an existing programme into new sites, PHARMExcel can help you assess feasibility, refine your protocol and plan delivery. To explore how our urology CRO services could support your next study, contact our team to arrange an initial discussion.
Urology CRO FAQs
What does a urology CRO do for sponsors?
A urology CRO provides specialist clinical trial governance and oversight for studies in urinary, pelvic floor and male reproductive conditions. For sponsors, this can include feasibility assessments, protocol review, regulatory and ethics submissions, project management, monitoring, safety oversight, data management and operational coordination across specialist urology sites. A CRO with urology experience understands the procedures, endpoints and patient considerations involved and can help translate that into a realistic, deliverable study plan.
Which urology conditions and indications can PHARMExcel oversee?
PHARMExcel can provide governance and oversight for clinical trials across a broad range of urology indications, including benign prostatic hyperplasia, prostate cancer, bladder cancer, urinary incontinence, voiding dysfunction, pelvic floor disorders, erectile dysfunction, Peyronie’s disease, nephrolithiasis and other urinary tract conditions. We work with sponsors to understand the target population, standard of care and study objectives, then align the trial with the most appropriate specialist centres and site pathways.
How does PHARMExcel approach recruitment in urology trials?
PHARMExcel does not directly recruit patients. Instead, we provide governance and oversight of site-level recruitment by helping sponsors identify the right sites, assess realistic referral pathways and work closely with investigators and research teams who know the local patient population. This is particularly important in urology studies, where symptom sensitivity, privacy concerns and the burden of participation can all influence enrolment and retention.
Can PHARMExcel oversee studies involving imaging, biopsies or specialist urology assessments?
Yes. Many urology trials depend on specialist assessments such as imaging, biopsies, urinary function testing, symptom monitoring tools or procedure-related follow up. PHARMExcel does not perform these assessments directly, but we provide governance and oversight by helping sponsors connect with sites and centres that have the right expertise, processes and infrastructure in place to deliver them consistently.
What endpoints and assessments are common in urology clinical trials?
Urology studies often rely on a combination of objective and subjective endpoints, depending on the indication and study phase. Common examples include urinary function measures, symptom scores, voiding diaries, patient-reported outcomes, imaging findings and quality of life assessments. In some studies, these are combined with procedural or anatomical endpoints to provide a fuller picture of treatment effect. Clear site processes and consistent data collection are essential to making those results reliable and clinically meaningful.
How does PHARMExcel ensure quality and regulatory compliance in urology trials?
Our work is guided by a formal quality management system and adherence to GCP. For each urology study, we apply processes that are proportionate to the risk profile of the trial while maintaining clear oversight of site activity, protocol compliance, safety reporting and data quality. We also support sponsors with regulatory and ethics submissions and help ensure the study is delivered in line with UK regulatory expectations.
How does working with a smaller UK CRO benefit urology studies?
Working with a smaller CRO gives sponsors direct access to experienced senior staff, continuity of the same core team and shorter communication lines throughout the study. In urology trials, where protocols can be sensitive and site realities vary, this helps sponsors make faster, better informed decisions. Our familiarity with NHS and academic environments also helps align urology studies with real world site capacity and patient pathways.